Day One Biopharmaceuticals (DAWN) announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development. As Head of R&D and a member of the Executive Leadership Team, the Company’s research, development and medical affairs infrastructure will report to Dr. Vasconcelles. Most recently, he was the Executive Vice President and Head of Research, Development, and Medical Affairs at ImmunoGen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals Approves Key Proposals at Annual Meeting
- Positive Outlook for Day One Biopharmaceuticals’ Ojemda: A Promising First-Line Treatment for Pediatric Glioma
- Buy Rating for Day One Biopharmaceuticals Driven by FDA Approval and Strong Market Potential
- Promising Future for Day One Biopharmaceuticals: Buy Rating on Ojemda’s Potential in Pediatric Brain Tumors
- Day One Biopharma’s Earnings Call Highlights Growth